|
|
|
|
|
|
|
|
|
|
|
| Experimental Information | |
| Enzymatic Activity | |
| Molecule Id | EGIN0000649 |
| PMID | 17062696 |
| Assay Used | Recombinant protein Kinases, aswell as in cell proliferation assays |
| Experimently Validated | Yes |
| EGFR (IC50) | 22 /L nM |
| HER2 (IC50) | 32 nM |
| HER4 (IC50) | 190 nM |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes the Preclinical Antitumor Activity of BMS-599626 Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. |
| Extra | - |
| Cellular Activity | ||||||||||||||
| S.No. | Cell Line | Desp. | IC50 | IC80 | ED50 | GI50 | GI90 | EC50 | Kd | Inhibition (%) | Inhibitory Conc. | |||
| 1 | A2780 | - | > 10000 nM | - | - | - | - | - | - | - | - | |||
| 2 | AU565 | - | 630 nM | - | - | - | - | - | - | - | - | |||
| 3 | BT474 | - | 310 nM | - | - | - | - | - | - | - | - | |||
| 4 | GEO | - | 900 nM | - | - | - | - | - | - | - | - | |||
| 5 | HCC1419 | - | 750 nM | - | - | - | - | - | - | - | - | |||
| 6 | HCC1954 | - | 340 nM | - | - | - | - | - | - | - | - | |||
| 7 | HCC202 | - | 940 nM | - | - | - | - | - | - | - | - | |||
| 8 | KPL-4 | - | 380 nM | - | - | - | - | - | - | - | - | |||
| 9 | MDA-MB-175 | - | 840 nM | - | - | - | - | - | - | - | - | |||
| 10 | MRC5 | - | > 10000 nM | - | - | - | - | - | - | - | - | |||
| 11 | N87 | - | 450 nM | - | - | - | - | - | - | - | - | |||
| 12 | PC9 | - | 340 nM | - | - | - | - | - | - | - | - | |||
| 13 | Sal2 | - | 240 nM | - | - | - | - | - | - | - | - | |||
| 14 | ZR-75-30 | - | 510 nM | - | - | - | - | - | - | - | - | |||
| Activity against Receptor | |
| EGFR | Yes |
| HER2 | Yes |
| HER4 | Yes |
| Wild type | Yes |
| Mutant | - |
| Inhibitor Binding | |
| EGFR | - |
| HER2 | - |
| HER4 | - |